Skip to main content
. 2020 Aug 18;11(33):3105–3117. doi: 10.18632/oncotarget.27684

Table 1. Demographics of Phase II patients (safety analysis set).

Cohort 1 (NSCLC) Cohort 2 (biliary tract cancer) Cohort 3 (bladder cancer) Totala
N = 33 N = 49 N = 12 N = 97
Age, years, median (range) 61.0 (34–79) 64.0 (35–76) 65.0 (46–80) 63.0 (34–80)
Gender, No. (%)
 Male 26 (78.8) 31 (63.3) 11 (91.7) 70 (72.2)
 Female 7 (21.2) 18 (36.7) 1 (8.3) 27 (27.8)
Race, No. (%)
 White 33 (100) 44 (89.8) 11 (91.7) 90 (92.8)
 Black 0 1 (2.0) 1 (8.3) 3 (3.1)
 Asian 0 2 (4.1) 0 2 (2.1)
 Other 0 2 (4.1) 0 2 (2.1)
ECOG at baseline, No. (%)
 Grade 0 2 (6.1) 9 (18.4) 4 (33.3) 16 (16.5)
 Grade 1 31 (93.9) 40 (81.6) 8 (66.7) 81 (83.5)
Number of patients with at least one prior chemotherapy 3 (9.1) 3 (6.1) 3 (25.0) 10 (10.3)
Number of patients with at least one prior radiation 11 (33.3) 3 (6.1) 1 (8.3) 15 (15.5)
Number of patients with at least one surgical procedure 12 (36.4) 31 (63.3) 10 (83.3) 56 (57.7)

aOne patient in each cohort was diagnosed incorrectly, resulting in assignment to the incorrect cohort. These patients are not included in the cohort safety analysis summaries but are included in the total patient number since they received study treatments.